Major Events - Fuhong Hanlin (02696) received NMPA approval for the Phase I clinical trial application of HLX15-SC for the treatment of multiple myeloma [1] - Kangzheng Pharmaceutical (00867) signed an exclusive distribution agreement for the original drug Lidoderm® lidocaine gel patch [1] - MicroPort Robotics-B (02252) surpassed 200 global commercial orders for the Tumai® laparoscopic surgical robot [1] - BGO Group (08220) plans to acquire a proposal from Stephen Chow at a discount of approximately 91.79% [1] - Kogee Pharmaceuticals-B (02171) signed a strategic cooperation agreement with Shanghai Jinguang Enterprise Development to build a commercial production base for CAR-T cell therapy products in Jinshan [1] Operating Performance - China Resources Land (01109) reported total contract sales of approximately 11.65 billion yuan in January, a year-on-year increase of 0.4% [1] - Hua Hong Semiconductor (01347) announced a profit attributable to the parent company of 54.881 million USD for 2025, a year-on-year decrease of 5.6% [1] - China Coal Energy (01898) reported coal sales of 20.05 million tons in January, a year-on-year decrease of 7.3% [1] - China Metallurgical Group (01618) signed new contracts worth 73.65 billion yuan in January [1] - China Communications Construction (01800) reported new contracts worth 1.883672 trillion yuan for 2025, a year-on-year increase of 0.13% [1]

Core Viewpoint - Kangzheng Pharmaceutical (00867.HK) has signed an exclusive distribution agreement for Lidoderm® with Teikoku PharmaUSA, Inc., granting the company exclusive rights in the target region of mainland China for a period of ten years, with potential for renewal [1] Group 1: Agreement Details - The agreement is established between Kangzheng Pharmaceutical and Teikoku PharmaUSA, Inc., a subsidiary of Teikoku Seiyaku Co., Ltd [1] - The product involved in the agreement is Lidoderm® (lidocaine transdermal system) [1] - The cooperation period begins from the first commercial sale of the product in the target region and lasts for ten years, with options for renewal as per the agreement [1] Group 2: Responsibilities - Kangzheng Pharmaceutical will hold exclusive distribution rights in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - Teikoku PharmaUSA, Inc. is responsible for the production and supply of the product [1]

自願性及業務進展公告 簽訂原研藥Lidoderm®利多卡因凝膠貼膏獨家經銷協議 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生 或因倚賴該等內容而引致的任何損失承擔任何責任。 China Medical System Holdings Limited（「本公司」，連同其附屬公司統稱為「本集團」） 欣然宣佈，於二零二六年二月十二日，本集團通過本公司附屬公司與 Teikoku Pharma USA, Inc.（「TPU」, 為日本 Teikoku Seiyaku Co., Ltd（「TSC」，帝國製藥）之附屬公 司，以下合稱「合作方」）就 Lidoderm®利多卡因凝膠貼膏（「產品」）簽訂獨家經銷 協議（「協議」）。 根據協議，本集團獲得該產品在中華人民共和國（就本協議而言，不含香港特別行政區、 澳門特別行政區及臺灣地區，以下簡稱（「目標區域」）內的獨家經銷權利，合作方負 責該產品的生產及供應相關事宜。本協議合作期限首期自該產品在目標區域內首次商業 銷售之日起計十年，到期後根據協議約定續期。 Lidoder ...